Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442264 | 0.89 | PDE5A (0.69) | PDE5A | |
| SCHEMBL3583205 | 0.89 | PDE5A (0.65) | PDE5A | |
| Gisadenafil SCHEMBL120995 | 0.87 | PDE5A (1.00) | PDE5A | |
| Gisadenafil SCHEMBL29379724 | 0.87 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6448122 | 0.86 | PDE5A (0.60) | PDE5A | |
| SCHEMBL6443699 | 0.85 | PDE5A (0.74) | PDE5A | |
| SCHEMBL6445191 | 0.85 | PDE5A (0.65) | PDE5A | |
| SCHEMBL6442996 | 0.85 | PDE5A (0.78) | PDE5A | |
| SCHEMBL3583755 | 0.84 | PDE5A (0.89) | PDE5A | |
| SCHEMBL6446241 | 0.84 | PDE5A (0.80) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | claimed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | claimed |
| EP-1220856-B1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | claimed |
| US-20040152712-A1 | Pharmaceutically active compounds | PFIZER INC. | 2004-08-05 | — | — | US | claimed |
| US-6677335-B1 | PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS | PFIZER INC | 2004-01-13 | — | — | US | claimed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | claimed |
| US-6271228-B1 | ADMINISTERING PHOSPHODIESTERASE INHIBITOR | PFIZER INC. | 2001-08-07 | — | — | US | claimed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | claimed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-6677335-B1 | PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS | PFIZER INC | 2004-01-13 | — | — | US | disclosed |
| US-20030166662-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2002-11-07 | — | — | US | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| US-6271228-B1 | ADMINISTERING PHOSPHODIESTERASE INHIBITOR | PFIZER INC. | 2001-08-07 | — | — | US | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | PDE5A 1/4885 |
| US-20030166662-A1 | Treatment of the insulin resistance syndrome | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | PDE5A 1/4885 |
| US-20040152712-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885 |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.